Intco Medical Technology Stock: Valuation and P/E
300677.SZIntco Medical Technology trades at a P/E of 108.9 (Healthcare sector median 30.9, own median of recent years 18.1).
Daily figure as of 20 Nov 2026
P/E on Expected Earnings
The forward P/E of 12.9 divides the price by the earnings per share that 3 analysts expect on average for the next twelve months: $0.59. The twelve months are made up pro rata of the estimates for fiscal 2026 and 2027. The P/E of 108.9, by contrast, uses reported earnings for the last twelve months.
Analysts mostly estimate adjusted earnings, excluding amortization of acquisitions and other one-off items. The estimates change all the time; they are no promise and no price target.
Against Its Own Valuation History
Each fiscal year is shown with its P/E on the year-end date, using the price at the time. From 2017 to 2025 the P/E at fiscal year end ranged from 4.2 (2021) to 40.3 (2023).
P/E at Each Fiscal Year End
Figures as a table
| Year | P/E |
|---|---|
| 2017 | 28.6 |
| 2018 | 15.1 |
| 2019 | 18.1 |
| 2020 | 7.7 |
| 2021 | 4.2 |
| 2022 | 21.2 |
| 2023 | 40.3 |
| 2024 | 11.2 |
| 2025 | 24.6 |
P/E of Industry Peers
| Stock | P/E | Own median |
|---|---|---|
| Asahi Intecc | 32.3 | 54.7 |
| Teleflex | 77.6 | 37.7 |
| Gan & Lee Pharmaceuticals. | 31.6 | 42.4 |
| Merit Medical Systems | 31.8 | 56.4 |
| Intco Medical Technology | 108.9 | 18.1 |
| ICU Medical | 73.3 | 50.2 |
| Stevanato Group | 28.3 | 37.3 |
| Envista Holdings | 6.0 | 27.6 |
| SCHOTT Pharma | 24.6 | 31.0 |
The eight peers closest in market value, largest first. Trailing twelve-month P/E as of 20 Nov 2026, loss makers have none.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
